Teva entered pharma licensing with Takeda to commercialize Teva’s innovative glatiramer acetate formulation for the treatment of multiple sclerosis, in Japan.
Teva and Takeda are currently working on further agreements in connection with the implementation of this licensing deal.
Teva’s glatiramer acetate is designated as an orphan drug in Japan.
Under development as an Unapproved New Drug by Teva Pharmaceutical at the request of the Japanese Ministry of Health, Labor and Welfare.
Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan.
The financial details of the agreement are confidential.
Read the full article on Business Wire
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Takeda
Report: Partnering Deals and Alliances with Teva
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity